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e-mail address: waseem_alzamil@hotmail.comWaseem M. Al Zamil ⇑AbstractAims: To determine the feasibility, safety, and clinical efficacy of intravitreal 0.7-mg dexamethasone implants (Ozurdex) in patients
with refractory cystoid macular edema after uncomplicated cataract surgery.
Methods and materials: In this study, 11 eyes of 11 patients affected by pseudophakic cystoid macular edema refractory to med-
ical treatment were treated with a single intravitreal injection of a dexamethasone implant. Follow-up visits involved Early Treat-
ment Diabetic Retinopathy Study visual acuity testing, optical coherence tomography imaging, and ophthalmoscopic examination.
Results: The follow-up period was six months. The mean duration of cystoid macular edema before treatment with Ozurdex was
7.7 months (range, 6–10 months). The baseline mean best corrected visual acuity (BCVA) was 0.58 ± 0.17 logarithm of the mini-
mum angle of resolution (logMAR). The mean BCVA improved to 0.37 ± 0.16 logMAR (p = 0.008) and 0.20 ± 0.13 logMAR
(p = 0.001) after 1 and 3 months, respectively. At the last follow-up visit (6-month follow-up), the mean BCVA was 0.21 ± 0.15
logMAR (p = 0.002). The mean foveal thickness at baseline (513.8 lm, range, 319–720 lm) decreased significantly (308.0 lm;
range, 263–423 lm) by the end of the follow-up period (p < 0.0001). Final foveal thickness was significantly correlated with base-
line BCVA (r = 0.57, p = 0.002). No ocular or systemic adverse events were observed.
Conclusions: Short-term results suggest that the intravitreal dexamethasone implant is safe and well tolerated in patients with
pseudophakic cystoid macular edema. Treated eyes had revealed a significant improvement in BCVA and decrease in macular
thickness by optical coherence tomography.
Keywords: Intravitreal dexamethasone implant, Ozurdex, Refractory pseudophakic cystoid macular edema, Cataract surgery
 2014 The Author. Production and hosting by Elsevier B.V. on behalf of Saudi Ophthalmological Society, King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
http://dx.doi.org/10.1016/j.sjopt.2014.10.005Introduction
Cystoid macular edema (CME) is a common cause of
decreased vision following complicated or uncomplicated
cataract surgery. It may be revealed angiographically after
uneventful intracapsular and extracapsular cataract surgery
in up to 60% and 30% of cases, respectively; however, the
incidence of clinical CME is much lower (0.1–13%).1–4 Therate of angiographic and clinical CME after phacoemulsifica-
tion cataract surgery is even lower at 20% and 1–2%,
respectively.4,5
CME usually resolves spontaneously in approximately 90%
of eyes, and only a small subset of patients suffer permanent
visual morbidity.4,6 Considering the large number of patients
undergoing cataract surgery, this small percentage of patients
represents a population large enough to drive ongoinge:
al.com
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Various treatment modalities including topical, systemic,
periocular, and intraocular steroids; topical non-steroidal
anti-inflammatory drugs (NSAIDs); and systemic carbonic
anhydrase inhibitors (CAIs) have been used with different
success rates to treat pseudophakic CME.3–5
The pathogenesis of pseudophakic CME is thought to be
multifactorial. However, the major etiology appears to
involve inflammatory mediators that are upregulated in the
aqueous and vitreous humors after surgical manipulation.
Inflammation breaks down the blood–aqueous and blood–
retinal barriers, which leads to increased vascular permeabil-
ity.7 Eosinophilic transudate accumulates in the outer plexi-
form and inner nuclear layers of the retina to create cystic
spaces that coalesce to form larger pockets of fluid. In
chronic CME, lamellar macular holes and subretinal fluid
may also form.1
Glucocorticoids such as dexamethasone exert their anti-
inflammatory effects by influencing multiple signal transduc-
tion pathways, including VEGF.8–11 By binding to cytoplasmic
glucocorticoid receptors, corticosteroids in high doses
increase the activation of anti-inflammatory genes, whereas,
at low concentrations, they play a role in the suppression of
activated inflammatory genes.9–12
The dexamethasone implant (Ozurdex; Allergan, Inc.,
Irvine, CA) is a novel approach approved by the United States
Food and Drug Administration (FDA) and by the European
Union (EU) for the intravitreal treatment of macular edema
(ME) after branch or central retinal vein occlusion and for
the treatment of noninfectious uveitis affecting the posterior
segment of the eye.13–15 Furthermore, its clinical efficacy has
been documented in other diseases, such as diabetic ME and
persistent ME associated with uveitis or Irvine–Gass syn-
drome.16–21 Compared with other routes of administration
of dexamethasone analogs, intravitreal administration of this
implant has been found to be more advantageous.22 The key
features of the drug delivery system (DDS) are the sustained-
release formulation of the poly lactic acid-co-glycolic acid
(PLGA) matrix material, which dissolves completely in vivo,
and the single-use applicator for intravitreal placement.23
The primary purpose of this study was to evaluate the
effectiveness, safety, and feasibility of a single intravitreal
injection of Ozurdex over 6 months in patients with persistent
CME resulting from Irvine–Gass syndrome following unevent-
ful cataract surgery.Subjects and methods
This retrospective case series comprised 11 eyes of 11
patients with CME after cataract surgery refractory to current
standard treatment who received a single injection of
Ozurdex between June 2011 and March 2014 at King Fahd
Hospital of the University, Khobar, Saudi Arabia. The study
was approved by the Institutional Review Board of the Uni-
versity of Dammam and the ethics committee.
Informed consent was obtained from the patients. The
nature of off-label use of Ozurdex for CME after cataract sur-
gery and its potential side effects were extensively discussed
with the patients before obtaining informed consent.
Inclusion criteria included having previously undergone a
wide range of treatment options, including oral CAIs, topical
therapy with NSAIDs and corticosteroids, as well as intravitre-al treatment either with anti-VEGF agents or with intravitreal
triamcinolone. Refractory CME was defined as persistent
CME with foveal thickness (FT) more than 250 lm and intra-
retinal cystic changes revealed by spectral-domain optical
coherence tomography (SD-OCT), lasting for at least 90 days
after initiation of treatment. Exclusion criteria included
diagnosis of systemic disease such as diabetes mellitus, his-
tory of other intraocular surgery before cataract extraction,
glaucoma, elevated intraocular pressure (IOP), and vitreoret-
inal pathology such as epiretinal membrane or vitreomacular
traction in the study eye, which could prevent improvement
in visual acuity.
In all patients, the best corrected visual acuity (BCVA) was
measured by using Early Treatment Diabetic Retinopathy
Study charts and an ophthalmic examination, including slit-
lamp biomicroscopy. Fluorescein angiography was also per-
formed, showing leakage in the central region typical for
CME. Baseline central retinal characteristics were analyzed
by optical coherence tomography SD-OCT (Stratus OCT-3,
Humphrey-Zeiss, San Leandro, CA) through a dilated pupil
by a retina specialist. Retinal thickness of the 1.0-mm central
retina was obtained from the macular thickness map for use
in further calculations. Patients received a dexamethasone
implant in the study eye at the baseline visit (day 1). The
eye was prepared in the standard manner, using 5% povi-
done/iodine and topical antibiotics (0.3% ciprofloxacin). A
single-use applicator with a 22-gauge needle was used to
place a dexamethasone implant in the vitreous chamber
through a self-sealing scleral injection. All injections were
performed in the operating room. Following the injection,
IOP and retinal artery perfusion were assessed, and patients
were instructed to use topical antibiotics for 5 days (0.5%
moxifloxacin). Patients were scheduled for regular postsurgi-
cal follow-up visits at day 2 and 1, 3, and 6 months. During
these follow-up visits, the patients underwent BCVA exami-
nation, OCT imaging, and ophthalmoscopic examination.
The primary efficacy outcome measure was the change in
BCVA and FT from baseline to 6 months. Statistical calcula-
tions were performed using the Statistical Package for Social
Sciences (version 20.0; SPSS Inc., Chicago, IL). Mean changes
from baseline FT and BCVA (converted to the logarithm of
the minimum angle of resolution [logMAR]) were analyzed
using paired t-tests. A 2-tailed test with an a level of 0.05
was used for all comparisons.Results
This study included 11 eyes of 11 consecutive patients
who were followed for 6 months. The baseline characteristics
of the patients and study eyes are listed in the Table 1. The
patients’ mean age was 59.4 ± 9.3 years, and 64% (7 of 11
patients) were men. All eyes had clinical CME at baseline
examination. Patients were unresponsive to previous treat-
ment with NSAIDs eyedrops, systemic CAIs, systemic or
topical steroids, as well as intravitreal treatment either with
anti-VEGF agents or with intravitreal triamcinolone. The
mean duration of CME before treatment with Ozurdex was
7.7 months (range, 6–10 months).
At baseline, the mean FT was 513.8 ± 134.9 lm. FT values
decreased to 371.6 ± 91.9 lm (mean ± SD, p = 0.001) at
1 month and 302.6 ± 50.9 lm (p = 0.002) at 3 months, and
increased slightly to 308.0 ± 54.5 lm (p = 0.031) at the end
Table 1. Baseline demographics and clinical features of the patients.
Patient
No.
Gender Age
(Years)
Duration of
CME Before
Ozurdex
Treatment
(Months)
BCVA (logMAR) Foveal thickness (lm) Intraocular pressure (mmHg)
Baseline Month
1
Month
3
Month
6
Baseline Month
1
Month
3
Month
6
Baseline Month
1
Month
3
Month
6
1 M 55 8 0.4 0.1 0.0 0.0 319 281 277 265 15 15 16 17
2 F 53 8 0.5 0.3 0.2 0.2 566 351 288 293 12 11 15 15
3 M 70 6 0.8 0.5 0.3 0.4 720 542 411 423 18 16 18 17
4 M 47 7 0.4 0.4 0.2 0.2 445 330 283 294 12 13 15 13
5 F 73 6 0.8 0.6 0.4 0.4 610 451 314 321 19 18 19 19
6 M 57 10 0.6 0.4 0.1 0.1 532 335 255 263 13 14 16 17
7 M 61 9 0.6 0.3 0.2 0.2 405 311 290 297 17 17 20 18
8 F 59 8 0.5 0.4 0.2 0.3 420 332 280 280 17 15 19 16
9 M 61 7 0.6 0.4 0.2 0.2 435 308 293 300 13 13 15 14
10 M 58 6 0.6 0.5 0.2 0.3 705 512 375 390 19 20 18 18
11 F 62 9 0.8 0.5 0.3 0.3 590 420 299 315 18 19 19 18
0
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0.2
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Figure 2. Mean changes from baseline BCVA. Improvement in BCVA
observed at 1, 3, and 6 months after the injection.
132 W.M. Al Zamilof the follow-up period. All of the FT reduction outcomes
were statistically significant, with respect to baseline data
(p < 0.05) (Fig. 1). The mean change from baseline FT was
142.2 lm (28% decrease) at 1 month and 211.2 lm (41%
decrease) and 205.8 lm (40% decrease) at 3 months and
6 months, respectively.
Furthermore, statistically significant improvement in BCVA
was observed at 1 month after treatment with the dexameth-
asone implant and at each subsequent follow-up visit (Fig. 2).
The baseline mean BCVA was 0.58 ± 0.17 logMAR. The mean
BCVA improved to 0.37 ± 0.16 logMAR (p = 0.008) and
0.20 ± 0.13 logMAR (p = 0.001) after 1 and 3 months, respec-
tively. At the last visit (6-month follow-up), the mean BCVA
was 0.21 ± 0.15 logMAR (p = 0.002). Final foveal thickness
(correlation coefficient, r = 0.57, p = 0.002) was significantly
correlated with baseline BCVA (Fig. 3). No serious ocular or
systemic side effects were noted during the observation per-
iod. There was no significant IOP elevation was observed in
any patient.
Discussion
CME can develop after modern cataract surgery. This
complication is an important cause of suboptimal postopera-
tive vision. Spontaneous resolution of the edema is the most
likely natural course in this pathology. However, up to 2% of
patients will not have spontaneous resolution of the edema
and must thus be treated. Prompt treatment on recognitionFigure 1. Mean changes from baseline foveal thickness. Improvement in
foveal thickness observed at 1, 3, and 6 months after the injection.of the disorder is warranted, because if ME has been present
for several months, there is likely irreversible changes in the
macula.24
In the current study, intravitreal treatment with a dexameth-
asone implant safely reduced ME and improved visual acuity in
a difficult-to-treat patient population with long-standing ME
caused by Irvine–Gass syndrome. By 1 month after treatment
with a dexamethasone implant, both mean FT and mean BCVA
had improved from baseline, and the improvement remained
statistically significant throughout the 6-month study period.
The peak effectiveness of the dexamethasone implant was
observed at 3 months after injection, when mean FT had
decreased by 41% and the mean BCVA improved to
0.20 ± 0.13 logMAR from baseline. Some patients did not
achieve normal FT and showed residual thickening at 6 months
after injection; these patients may require a second intravitreal
injection of the dexamethasone implant.
So far, only a few controlled clinical trials have evaluated
treatments for ME associated with Irvine–Gass syndrome,
including one on the use of vitrectomy for chronic aphakic
CME.25 Intravitreal triamcinolone has been widely studied
in diabetic ME and retinal vein occlusion; however, data sup-
porting its use in pseudophakic CME are lacking. In 2003,
Benhamou et al. reported the first study using 8-mg intravi-
treal triamcinolone to treat three cases of refractory chronic
pseudophakic CME and showed that FT and visual acuity
improved, but the effects were found to be transient.26
Another case series also reported transient benefits with
4-mg intravitreal triamcinolone.27 Clearly, one of the major
Figure 3. Final foveal thickness is positively correlated with baseline BCVA (r = 0.57, p = 0.002).
Dexamethasone implants for pseudophakic macular edema 133limitations of intravitreal corticosteroids is its transient effect
that necessitates repeated injections. This limitation can be
overcome by the currently available sustained-release dexa-
methasone implant.
Several other studies have focused on the treatment of
chronic pseudophakic CME that is refractory to other treat-
ments. In 2008, Spitzer et al. showed that 1.25-mg intravitreal
bevacizumab did not significantly improve visual outcomes in
a series of 16 eyes with refractory pseudophakic CME,
although a slight decrease in FT was observed.28 ‘‘Triple
therapy’’ with intravitreal triamcinolone, intravitreal bev-
acizumab, and topical NSAIDs has been also shown to be
effective, although the effects of the intravitreal medications
were transient.29
Sustained DDSs have been developed to address the
limitation of intravitreal corticosteroid injections. Ozurdex is
an injectable, biodegradable intravitreal DDS that provides
sustained release of preservative-free dexamethasone, a
potent corticosteroid.30 In 2009, the FDA approved its use
for the treatment of ME secondary to retinal vein occlusions,
and in 2010, it was approved for the treatment of noninfec-
tious posterior uveitis.13 A phase II study subgroup analysis
investigated its efficacy in the treatment of persistent ME
resulting from uveitis or pseudophakic CME.31 Twenty-seven
patients with refractory pseudophakic CME were recruited
and randomized to receive dexamethasone DDS 350 lg,
dexamethasone DDS 700 lg, or observation. Eight patients
showed at least a 10-letter improvement at day 90 and main-
tained the improvement at day 180. Significance testing was
performed with combined data from pseudophakic CME and
uveitis patients: an improvement in BCVA of at least 10 let-
ters at day 90 was seen in 42% in the 350-lm group
(p = 0.117) and 54% in the 700-lm group (p = 0.029).
Similarly, the results of this study are consistent with those
results named above. Indeed, the dexamethasone implant
resulted in sustained levels of dexamethasone release and
biological activity for 6 months, with peak drug activity occur-
ring over the first three months.18–20 The target population inthe current study was difficult to treat because it included
severe cases of long-standing ME after cataract surgery,
which had failed to respond to a wide range of treatment
options including oral CAIs, topical therapy with NSAIDs,
and corticosteroids, as well as intravitreal treatment, most
commonly intravitreal injection of the corticosteroid triamcin-
olone or anti-VEGF therapy.
The treatment approach for ME has been dynamic. Over
the past few decades, corticosteroids have raised interest
in the treatment of ME because of their anti-inflammatory
effects and because they inhibit VEGF synthesis and reduce
vascular permeability. Nonetheless, due to safety concerns
(i.e., the risk of IOP elevation and cataract progression), in
recent years, the use of corticosteroids has been drastically
reduced in most developed countries. Recently, the safety
profile of Ozurdex, which is currently approved for the treat-
ment of retinal vein occlusion, was addressed in the GENEVA
study.13 In the present series, no major side effects were
recorded, and dexamethasone intravitreal implants were
found to be well tolerated.
This study has several limitations—being a short-term,
open-label, uncontrolled, and retrospective study—that pre-
cluded any estimation of the long-term efficacy or safety of
intravitreal Ozurdex. A significant limitation of this study is
that it included only a relatively small number of patients
(11 eyes). In conclusion, intravitreal Ozurdex can induce
regression of chronic refractory CME with concomitant
improvement in visual acuity. This may be an excellent and
safe treatment modality for patients with refractory CME
unresponsive to previous treatment with NSAIDs eyedrops,
systemic CAIs, systemic or topical steroids, as well as intravi-
treal treatment either with anti-VEGF agents or intravitreal
triamcinolone.Conflict of interest
The authors declared that there is no conflict of interest.
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